Physician profile
John P Lazoritz
NPI 1124446166
$16,118.54
in general payments reported to CMS, 2019-2025
18 companies · $591 in 2025
The $591 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,886 · 2020: $199 · 2021: $2,419 · 2022: $1,102 · 2023: $3,475 · 2024: $4,447 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $3,009 · Travel and Lodging: $2,935 · Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $3,009.49 |
| Travel and Lodging | $2,935.15 |
| Food and Beverage | $2,568.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $6,183.10 | 2019-2025 | Fixos, Star, Axsos |
| Arthrex, INC. | $3,937.84 | 2019-2021 | |
| Integra Lifesciences Corporation | $3,161.54 | 2020-2025 | Integra, Acell, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $825.14 | 2019-2025 | Grafix Pl, Stravix, Stravix Pl |
| Conetic Solutions, INC. | $758.33 | 2021-2025 | |
| Rsw Medical Company, INC. | $741.56 | 2019 | |
| Organogenesis INC. | $218.46 | 2021-2024 | Affinity, Puraply |
| Averitas Pharma INC. | $59.74 | 2023-2025 | Qutenza |
| Horizon Therapeutics Plc | $54.55 | 2019-2020 | |
| Amgen INC. | $40.02 | 2021-2022 | |
| Misonix INC | $26.82 | 2020 | |
| Osiris Therapeutics INC. | $20.15 | 2019 | |
| Orthofix Medical, INC. | $19.58 | 2019 | |
| Bioventus LLC | $15.65 | 2025 | Exogen Ultrasound Bone Healing System |
| Insulet Corporation | $15.61 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $14.86 | 2021 | |
| Morphosys, US INC. | $13.64 | 2021 | |
| Kerecis Limited | $11.95 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lazoritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.